Glaukos : Investor Presentation November 2022

Investor Presentation

NOVEMBER 2022

2 © 2022 Glaukos Corporation

Disclaimer

All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management's current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, uncertainties regarding the duration and severity of the COVID-19 pandemic and its impact on our business or the economy; the impact of general macroeconomic conditions; the reduced physician fee and ASC facility fee reimbursement rate finalized by CMS for 2022 and 2023 for procedures utilizing the Company's iStent family of products and its impact on our U.S. combo-cataract glaucoma revenue; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, pandemic or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by government or third-party payors for procedures using the iStent®, the iStent inject® W, iAccess, iPRIME, iStent infinite, our corneal cross-linking products or other products in development; our ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products; our ability to compete effectively in the highly competitive and rapidly changing medical device industry and against current and future technologies (including MIGS technologies); our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness.

These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, which was filed with the SEC on November 4, 2022. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this presentation are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this presentation, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Attractive Financial Profile Provides Solid Foundation

TOTAL NET SALES		SALES MIX
(in millions)	$294
	US Glaucoma
		Int'l Glaucoma
	7-Yr CAGR:	5%	Corneal Health
	30%	Q3 2015
$46

					95%
	2014		2021

Q3 2022

25%

52%

23%

SCALE

BALANCE SHEET

MARGINS

DIVERSIFICATION

GROSS MARGIN1	2015	CASH AND EQUIVALENTS2
75% 84%	$104
		(in millions)

2014

2022

2022

$371

1 FY2014 GAAP & non-GAAP gross margin (75%); 3Q 2022 GAAP gross margin of 76% was adjusted for certain Avedro merger-related accounting and other adjustments - see Appendix for details; 2 2015 as of 6/30; 2022 as of 9/30

4 © 2022 Glaukos Corporation

2022: Entering the Next Phase of Our Pioneering Journey

Expanding Core Offering & Potential

• Combo-cataractevolution
• Standalone glaucoma entry
• International glaucoma, iLink market- building initiatives take hold

Multiple Pharma Programs Move to Clinic

• Phase 2 trials
  (dry eye, presbyopia, iLink third-gen)
• IND/IDE filings planned (glaucoma and other programs)

CORE	NEAR-TERM	NEW R&D	GLOBAL
PLATFORMS &
FRANCHISES	PIPELINE	ORGANIZATION
PROGRAMS

New Pharma Products on Deck	Preparing for Future Growth
•	iDose TR Phase 3 data release	•	New HQ; manufacturing expansions
•	iDose TR pre-NDA submission activities	•	Global talent and expertise
	ongoing

5 © 2022 Glaukos Corporation